A multicentric pharmacovigilance study collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients

Agnese Gugliandolo, Federica Longo, Maria Giovanna Marrosu, Giovanni Luigi Mancardi, Ilaria Gandoglia, Maurizio Melis, Fabrizio Lo Giudice, Placido Bramanti, Emanuela Mazzon

Research output: Contribution to journalArticle

Abstract

Purpose: We performed a pharmacovigilance study of 10 drugs used in patients with relapsing-remitting multiple sclerosis (RR-MS). Our aim was to provide an overview of the safety of these drugs by the evaluation of reported expected and unexpected adverse reactions.

Patients and methods: We collected and analyzed adverse drug reactions from RR-MS patients belonging to four hospitals in three Italian regions, for a period of 24 months.

Results: We received a total of 411 adverse reactions, of which 84.18% were expected and only 15.82% were unexpected. We found no correlation between the number of reported adverse reactions and the route of administration (injectable/intravenous drugs N=224, oral drugs N=187). However, oral agents have caused a greater number of unexpected moderate-to-severe adverse reactions while, in injectable and infusion therapies, they have been evaluated as mild-moderate adverse reactions.

Conclusion: Our results underscore the importance of monitoring the safety profile of multiple sclerosis therapies, with particular attention to oral agents that have been introduced later in the clinical practice.

Original languageEnglish
Pages (from-to)1765-1788
Number of pages24
JournalTherapeutics and Clinical Risk Management
Volume14
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'A multicentric pharmacovigilance study collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients'. Together they form a unique fingerprint.

  • Cite this